Global Genito-urinary Drugs Market Briefing 2017-2022 - Research and Markets

01/03/18 01:58 PM EST

Global Genito-urinary Drugs Market Briefing 2017-2022 - Research and Markets

The "Genito-urinary Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global genito-urinary drugs market is expected to reach around $75 billion in 2020.

This growth is mainly due to the growing genitourinary disorders like chronic kidney disease CKD and also going forward, the number of pipeline drugs (ABT-614, Abbott Laboratories and EOS789, Chugai Pharmaceutical) are expected to increase with constant improvements in healthcare infrastructure. Novel drugs such as Cialis which are considerably more effective than the drugs used in multiple-drug therapies, and are affordable in cost are expected to fuel the growth of this market.

Demand For Combination Products - The launch of combination products for the treatment of urinary tract infections is an emerging trend in the genito-urinary disorder drugs market. Competitors in the market are developing combination drugs to fight multi-drug resistant bacteria and also expanding indications for existing drugs for the treatment of genito-urinary disorders.

For instance, Merck Sharp & Dohme Corp. offers ZERBAXA, a combination drug of a novel cephalosporin and a beta-lactamase inhibitor used for the treatment of complicated urinary tract infections.


  • Markets Covered: Hormonal contraceptives, Drugs For Hormonal Replacement Therapy, Drugs For Infections And Others, Drugs for Benign prostatic hypertrophy, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs for Infertility, and Diuretics
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Daiichi Sankyo Company
  • Pfizer Inc.
  • Bayer AG
  • Astellas Pharma Inc.
  • Allergan Plc.
  • Otsuka Pharmaceutical Co. Ltd.
  • GlaxosmithKline Plc.
  • Sanofi S.A.

For more information about this report visit

Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Urological Disorders Drugs